Urinary albumin excretion is associated with true resistant hypertension

Journal of Human Hypertension

Volumn 24, Issue 1, 2010, Pages 27-33

  Oliveras, A ^a,d   Armario, P ^b   Hernandez Del Rey R ^b   Arroyo, J A ^c   Poch, E ^b   Larrousse, M ^b   Roca Cusachs, A ^c   De La Sierra, A ^b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d NONE   (Spain)

Author keywords

Ambulatory blood pressure monitoring; Microalbuminuria; Resistant hypertension; Urinary albumin excretion; White coat resistant hypertension

Indexed keywords

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MONITORING; CROSS-SECTIONAL STUDY; DRUG RESISTANCE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL; URINE;

ADULT; AGED; ALBUMINURIA; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 77449146751     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.35     Document Type: Article

References (36)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al., the National High Blood Pressure Education Program Coordinating Committee. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2575.
3. Muxfeldt ES, Bloch KV, Nogueira Ada R, Salles GF. True resistant hypertension: is it possible to be recognized in the office? Am J Hypertens 2005; 18(12 Pt 1): 1534-1540.
4. Hernández del Rey R, Armario P, Martín-Baranera M, Castellanos P. Clustering of cardiovascular risk factors and prevalence of metabolic syndrome in subjects with resistant hypertension. Med Clin (Bare) 2006; 127: 241-245.
5. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens 2001; 14: 1263-1269.
6. Kaplan NM. Resistant hypertension. J Hypertens 2005; 23: 1441-1444.
7. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063-2070.
8. Hernández del Rey R, Armario P, Martín-Baranera M, Sánchez P, Cárdenas G, Pardell H. Target-organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white-coat effect. Blood Press Monit 1998; 3: 331-337.
9. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18: 1422-1428.
10. Redón J, Campo C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31: 712-718.
11. Salles GF, Cardoso CRL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008; 168: 2340-2346.
12. Salles GF, Fiszman R, Cardoso CRL, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 2007; 50: 723-728.
13. Nogueira AD, Fernandes AS, Coutinho ES, Salles GF, Muxfeld ES, Bloch KV. Factors associated with microalbuminuria in resistant hypertension. Int J Cardiol 2007; 121: 86-87.
14. ASE Committee Recommendations. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standard Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
16. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-35.
17. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
18. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-906.
19. Ärnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals. The Framingham Heart Study. Circulation 2005; 112: 969-975.
20. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant Hypertension: Diagnosis, Evaluation and Treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419.
21. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm Jr RH et al. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension 2001; 37: 12-18.
22. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
23. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit 2003; 8: 181-185.
24. Agarwal R, Andersen MJ. Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension 2005; 46: 514-520.
25. Sarafidis PA, Bakris GL. Resistant hypertension. An overview of evaluation and treatment. J Am Coll Cardiol 2008; 52: 1749-1757.
26. Yuyun MF, Adler AI, Wareham NJ. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? Curr Opin Nephrol Hypertens 2005; 14: 271-276.
27. Palatini P, Graniero GR, Mormino P, Mattarei M, Sanzuol F, Cignacco GB et al. Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST Study). Am J Hypertens 1996; 9(4 Pt 1): 334-341.
28. Palatini P, Canali C, Dorigatti F, Baccillieri S, Giovinazzo P, Roman E et al. Target organ damage and ambulatory blood pressure in stage I hypertension. The Hypertension and Ambulatory Recording Venetia Study. Blood Press Monit 1997; 2: 79-88.
29. Martínez MA, Moreno A, Aguirre de Carcer A, Cabrera R, Rocha R, Torre A et al. Frequency and determinants of microalbuminuria in mild hypertension: a primary-care based study. J Hypertens 2001; 19: 319-326.
30. Wiinberg N, Bang LA, Wachtell K, Larsen J, Olsen MH, Tuxen C et al. 24-h Ambulatory blood pressure in patients with ECG-determined left ventricular hypertrophy: left ventricular geometry and urinary albumin excretion-a LIFE substudy. J Hum Hypertens 2004; 18: 391-396.
31. Bakris G. Proteinuria: a link to understanding changes in vascular compliance? Hypertension 2005; 46: 473-474.
32. Kramer H, Jacobs Jr DR, Bild D, Post W, Saad MF, Detrano R et al. Urine albumin excretion and sub-clinical cardiovascular disease. The Multi-Ethnic Study of Atherosclerosis. Hypertension 2005; 46: 38-43.
33. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
34. Klausen K, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46: 33-37.
35. Hallan S, Astor B, Romundstad S, Aasarod K, Kvenild K, Coresh J. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals. The HUNT II Study. Arch Intern Med 2007; 167: 2490-2496.
36. Agarwal R, Bunaye Z, Bekele DM. Prognostic significance of between-arm blood pressure differences. Hypertension 2008; 51: 657-662.